The immunoglobulin market was valued for $13.5 billion in 2022 and is estimated to reach $25.6 billion by 2032, exhibiting a CAGR of 6.6% from 2023 to 2032. Immunoglobulins, commonly referred to as antibodies, are essential proteins produced by the immune system to safeguard the body against infections and diseases. These Y-shaped molecules play a fundamental role in the immune response by recognizing and binding to specific foreign substances, such as viruses, bacteria, and toxins. Comprising various classes-most notably IgG, IgA, IgM, IgD, and IgE-each immunoglobulin class serves distinct functions. IgG, the predominant type, provides long-lasting immunity, while IgM initiates rapid responses during the early stages of an infection. IgA is crucial for protecting mucosal surfaces, IgD aids in the maturation of B cells, and IgE is associated with allergic reactions. Collectively, immunoglobulins contribute to the body's defense mechanisms, marking invaders for destruction by other immune cells and playing a pivotal role in maintaining overall health and preventing a wide range of diseases.
The growth of the immunoglobulin market is primarily propelled by the escalating prevalence of life-threatening diseases, including immunodeficiency disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytopenic Purpura (ITP), and others. The increasing aging population, vulnerable to infections, further contributes to market expansion. Additionally, the expanding applications of immunoglobulins in treating autoimmune diseases and neurologic disorders play a pivotal role in driving market growth. These key factors collectively underscore the crucial role of immunoglobulins in addressing a diverse range of medical conditions, fueling innovation, and meeting the healthcare needs of a broad patient demographic.
Furthermore, the presence of reimbursement policies is further anticipated to potentially drive the market growth. Reimbursement policies play a pivotal role in facilitating patient access to immunoglobulin therapies by alleviating the financial burden associated with high treatment costs. As these policies provide financial support and coverage for immunoglobulin treatments, they enhance affordability for patients, making therapies more accessible and attractive for healthcare providers. Furthermore, reimbursement policies incentivize pharmaceutical companies to invest in research, development, and production, fostering innovation in the field. For instance, Octapharma USA received Medicare Part B approval of cutaquig 16.5% for adult primary immunodeficiency patients. In addition, owing to the approval, Octapharma increased its production of cutaquig by more than 45%, to meet patient needs. Thus, the presence of reimbursement policies not only benefit the patients but also incentivize pharmaceutical companies, thereby driving the market growth.
The immunoglobulin market is segmented on the basis of application, mode of delivery, distribution channel, and region. On the basis of application, the market is classified into primary immunodeficiency disease, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, Guillain-Barre syndrome and others. On the basis of mode of delivery, the market is categorized into intravenous, subcutaneous and intramuscular. The intravenous segment is further divided into 5% concentration, 10% concentration, and others. The subcutaneous segment is further divided into 16.5% concentration, 20% concentration, and others. Depending on distribution channel, the market is fragmented into hospital pharmacy, drug stores & retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major key players that operate in the global immunoglobulin market are CSL, Kedrion, SpA, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Limited, Taibang Biological Group Co., Ltd Grifols, S.A., Octapharma AG, Pfizer Inc., LFB Group, and Prothya Biosolutions.
The growth of the immunoglobulin market is primarily propelled by the escalating prevalence of life-threatening diseases, including immunodeficiency disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytopenic Purpura (ITP), and others. The increasing aging population, vulnerable to infections, further contributes to market expansion. Additionally, the expanding applications of immunoglobulins in treating autoimmune diseases and neurologic disorders play a pivotal role in driving market growth. These key factors collectively underscore the crucial role of immunoglobulins in addressing a diverse range of medical conditions, fueling innovation, and meeting the healthcare needs of a broad patient demographic.
Furthermore, the presence of reimbursement policies is further anticipated to potentially drive the market growth. Reimbursement policies play a pivotal role in facilitating patient access to immunoglobulin therapies by alleviating the financial burden associated with high treatment costs. As these policies provide financial support and coverage for immunoglobulin treatments, they enhance affordability for patients, making therapies more accessible and attractive for healthcare providers. Furthermore, reimbursement policies incentivize pharmaceutical companies to invest in research, development, and production, fostering innovation in the field. For instance, Octapharma USA received Medicare Part B approval of cutaquig 16.5% for adult primary immunodeficiency patients. In addition, owing to the approval, Octapharma increased its production of cutaquig by more than 45%, to meet patient needs. Thus, the presence of reimbursement policies not only benefit the patients but also incentivize pharmaceutical companies, thereby driving the market growth.
The immunoglobulin market is segmented on the basis of application, mode of delivery, distribution channel, and region. On the basis of application, the market is classified into primary immunodeficiency disease, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, Guillain-Barre syndrome and others. On the basis of mode of delivery, the market is categorized into intravenous, subcutaneous and intramuscular. The intravenous segment is further divided into 5% concentration, 10% concentration, and others. The subcutaneous segment is further divided into 16.5% concentration, 20% concentration, and others. Depending on distribution channel, the market is fragmented into hospital pharmacy, drug stores & retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major key players that operate in the global immunoglobulin market are CSL, Kedrion, SpA, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Limited, Taibang Biological Group Co., Ltd Grifols, S.A., Octapharma AG, Pfizer Inc., LFB Group, and Prothya Biosolutions.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the immunoglobulin market analysis from 2022 to 2032 to identify the prevailing immunoglobulin market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the immunoglobulin market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global immunoglobulin market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Application
- Primary Immunodeficiency Disease
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Guillain-Barre Syndrome
- Others
By Mode of Delivery
- Intravenous
- Type
- 5% concentration
- 10% concentration
- Others
- Subcutaneous
- Type
- 16.5% concentration
- 20% concentration
- Others
- Intramuscular
By Distribution Channel
- Hospital pharmacy
- Drug stores and retail pharmacy
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- CSL
- Kedrion, SpA
- Bio Products Laboratory Limited
- Grifols, S.A.
- Octapharma AG
- Pfizer Inc.
- Prothya Biosolutions
- Takeda Pharmaceutical Company Limited
- Taibang Biological Group Co., Ltd.
- LFB Group
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY
CHAPTER 6: IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: IMMUNOGLOBULIN MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- CSL
- Kedrion, SpA
- Bio Products Laboratory Limited
- Grifols, S.A.
- Octapharma AG
- Pfizer Inc.
- Prothya Biosolutions
- Takeda Pharmaceutical Company Limited
- Taibang Biological Group Co., Ltd.
- LFB Group
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
